antibodies
Biotech patents in 2026: align antibody claims with the experimental record
An antibody programme can generate valuable results long before the patent team has a coherent record of what was made, tested and disclosed. The difficulty is often the relationship between a promising candidate and the broader class the business wants to protect. A useful review connects claim language with experiments, supported alternatives and identifiable commercial…